ME02355B - Derivati 2-0ks0-1-pirolidinil imidazotiadiazola - Google Patents
Derivati 2-0ks0-1-pirolidinil imidazotiadiazolaInfo
- Publication number
- ME02355B ME02355B MEP-2016-44A MEP4416A ME02355B ME 02355 B ME02355 B ME 02355B ME P4416 A MEP4416 A ME P4416A ME 02355 B ME02355 B ME 02355B
- Authority
- ME
- Montenegro
- Prior art keywords
- methyl
- imidazo
- thiadiazol
- pyrrolidin
- trifluoromethyl
- Prior art date
Links
- -1 2-oxo-1-pyrrolidinyl imidazothiadiazole Chemical class 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 9
- ZSZAICVIWAXAGU-UHFFFAOYSA-N 1-[[6-chloro-2-(methoxymethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]methyl]-4-(3,3,3-trifluoropropyl)pyrrolidin-2-one Chemical compound ClC=1N=C2SC(COC)=NN2C=1CN1CC(CCC(F)(F)F)CC1=O ZSZAICVIWAXAGU-UHFFFAOYSA-N 0.000 claims 3
- JFQYRPAACGKFAB-UHFFFAOYSA-N 4-(2,2-difluoropropyl)-1-[[2-(methoxymethyl)-6-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]methyl]pyrrolidin-2-one Chemical compound FC(F)(F)C=1N=C2SC(COC)=NN2C=1CN1CC(CC(C)(F)F)CC1=O JFQYRPAACGKFAB-UHFFFAOYSA-N 0.000 claims 3
- HCJBZYUEYYNPLY-UHFFFAOYSA-N 4-(2-chloro-2,2-difluoroethyl)-1-[[6-(difluoromethyl)-2-(methoxymethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]methyl]pyrrolidin-2-one Chemical compound FC(F)C=1N=C2SC(COC)=NN2C=1CN1CC(CC(F)(F)Cl)CC1=O HCJBZYUEYYNPLY-UHFFFAOYSA-N 0.000 claims 3
- 150000002367 halogens Chemical group 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 2
- 125000004780 2-chloro-2,2-difluoroethyl group Chemical group [H]C([H])(*)C(F)(F)Cl 0.000 claims 2
- PFUPHHGNQRPLKX-UHFFFAOYSA-N 4-(2,2-difluoroethyl)-1-[[2-(methoxymethyl)-6-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]methyl]pyrrolidin-2-one Chemical compound FC(F)(F)C=1N=C2SC(COC)=NN2C=1CN1CC(CC(F)F)CC1=O PFUPHHGNQRPLKX-UHFFFAOYSA-N 0.000 claims 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- YOJWQYZGPUOMDQ-ZCFIWIBFSA-N (4r)-1-[[2-(hydroxymethyl)-6-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]methyl]-4-(2,2,2-trifluoroethyl)pyrrolidin-2-one Chemical compound FC(F)(F)C=1N=C2SC(CO)=NN2C=1CN1C[C@@H](CC(F)(F)F)CC1=O YOJWQYZGPUOMDQ-ZCFIWIBFSA-N 0.000 claims 1
- UBNLUHSOVONECH-SSDOTTSWSA-N (4r)-1-[[2-(methoxymethyl)-6-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]methyl]-4-(2,2,2-trifluoroethyl)pyrrolidin-2-one Chemical compound FC(F)(F)C=1N=C2SC(COC)=NN2C=1CN1C[C@@H](CC(F)(F)F)CC1=O UBNLUHSOVONECH-SSDOTTSWSA-N 0.000 claims 1
- WZUOWEYSJYNQFH-MRVPVSSYSA-N (4r)-1-[[2-(methoxymethyl)-6-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]methyl]-4-(3,3,3-trifluoropropyl)pyrrolidin-2-one Chemical compound FC(F)(F)C=1N=C2SC(COC)=NN2C=1CN1C[C@H](CCC(F)(F)F)CC1=O WZUOWEYSJYNQFH-MRVPVSSYSA-N 0.000 claims 1
- NJUMGOFCOKRBAR-ZCFIWIBFSA-N (4r)-4-(2-chloro-2,2-difluoroethyl)-1-[[2-(hydroxymethyl)-6-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]methyl]pyrrolidin-2-one Chemical compound FC(F)(F)C=1N=C2SC(CO)=NN2C=1CN1C[C@@H](CC(F)(F)Cl)CC1=O NJUMGOFCOKRBAR-ZCFIWIBFSA-N 0.000 claims 1
- DCXFIOLWWRXEQH-SSDOTTSWSA-N (4r)-4-(2-chloro-2,2-difluoroethyl)-1-[[2-(methoxymethyl)-6-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]methyl]pyrrolidin-2-one Chemical compound FC(F)(F)C=1N=C2SC(COC)=NN2C=1CN1C[C@@H](CC(F)(F)Cl)CC1=O DCXFIOLWWRXEQH-SSDOTTSWSA-N 0.000 claims 1
- DCXFIOLWWRXEQH-ISLPBHIQSA-N (4r)-4-(2-chloro-2,2-difluoroethyl)-1-[[2-(trideuteriomethoxymethyl)-6-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]methyl]pyrrolidin-2-one Chemical compound FC(F)(F)C=1N=C2SC(COC([2H])([2H])[2H])=NN2C=1CN1C[C@@H](CC(F)(F)Cl)CC1=O DCXFIOLWWRXEQH-ISLPBHIQSA-N 0.000 claims 1
- DCXFIOLWWRXEQH-AFBSGRQASA-N (4r)-4-(2-chloro-2,2-difluoroethyl)-1-[[2-[dideuterio(methoxy)methyl]-6-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]methyl]pyrrolidin-2-one Chemical compound FC(F)(F)C=1N=C2SC(C([2H])(OC)[2H])=NN2C=1CN1C[C@@H](CC(F)(F)Cl)CC1=O DCXFIOLWWRXEQH-AFBSGRQASA-N 0.000 claims 1
- DCXFIOLWWRXEQH-JTRFNHGFSA-N (4r)-4-(2-chloro-2,2-difluoroethyl)-1-[dideuterio-[2-(methoxymethyl)-6-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]methyl]pyrrolidin-2-one Chemical compound FC(F)(F)C=1N=C2SC(COC)=NN2C=1C([2H])([2H])N1C[C@@H](CC(F)(F)Cl)CC1=O DCXFIOLWWRXEQH-JTRFNHGFSA-N 0.000 claims 1
- XEYRQSWBGFZTDF-ZETCQYMHSA-N (4s)-1-[[2-(hydroxymethyl)-6-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]methyl]-4-(3,3,3-trifluoropropyl)pyrrolidin-2-one Chemical compound FC(F)(F)C=1N=C2SC(CO)=NN2C=1CN1C[C@@H](CCC(F)(F)F)CC1=O XEYRQSWBGFZTDF-ZETCQYMHSA-N 0.000 claims 1
- UBNLUHSOVONECH-ZETCQYMHSA-N (4s)-1-[[2-(methoxymethyl)-6-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]methyl]-4-(2,2,2-trifluoroethyl)pyrrolidin-2-one Chemical compound FC(F)(F)C=1N=C2SC(COC)=NN2C=1CN1C[C@H](CC(F)(F)F)CC1=O UBNLUHSOVONECH-ZETCQYMHSA-N 0.000 claims 1
- NJUMGOFCOKRBAR-LURJTMIESA-N (4s)-4-(2-chloro-2,2-difluoroethyl)-1-[[2-(hydroxymethyl)-6-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]methyl]pyrrolidin-2-one Chemical compound FC(F)(F)C=1N=C2SC(CO)=NN2C=1CN1C[C@H](CC(F)(F)Cl)CC1=O NJUMGOFCOKRBAR-LURJTMIESA-N 0.000 claims 1
- DCXFIOLWWRXEQH-ZETCQYMHSA-N (4s)-4-(2-chloro-2,2-difluoroethyl)-1-[[2-(methoxymethyl)-6-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]methyl]pyrrolidin-2-one Chemical compound FC(F)(F)C=1N=C2SC(COC)=NN2C=1CN1C[C@H](CC(F)(F)Cl)CC1=O DCXFIOLWWRXEQH-ZETCQYMHSA-N 0.000 claims 1
- MGLZIFNNAVCIGT-UHFFFAOYSA-N 1-[[2-(2-methoxyethyl)-6-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]methyl]-4-(2,2,2-trifluoroethyl)pyrrolidin-2-one Chemical compound FC(F)(F)C=1N=C2SC(CCOC)=NN2C=1CN1CC(CC(F)(F)F)CC1=O MGLZIFNNAVCIGT-UHFFFAOYSA-N 0.000 claims 1
- MLOCLGNNQDBGQT-UHFFFAOYSA-N 1-[[2-(2-methoxyethyl)-6-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]methyl]-4-(3,3,3-trifluoropropyl)pyrrolidin-2-one Chemical compound FC(F)(F)C=1N=C2SC(CCOC)=NN2C=1CN1CC(CCC(F)(F)F)CC1=O MLOCLGNNQDBGQT-UHFFFAOYSA-N 0.000 claims 1
- YOJWQYZGPUOMDQ-UHFFFAOYSA-N 1-[[2-(hydroxymethyl)-6-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]methyl]-4-(2,2,2-trifluoroethyl)pyrrolidin-2-one Chemical compound FC(F)(F)C=1N=C2SC(CO)=NN2C=1CN1CC(CC(F)(F)F)CC1=O YOJWQYZGPUOMDQ-UHFFFAOYSA-N 0.000 claims 1
- UBNLUHSOVONECH-UHFFFAOYSA-N 1-[[2-(methoxymethyl)-6-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]methyl]-4-(2,2,2-trifluoroethyl)pyrrolidin-2-one Chemical compound FC(F)(F)C=1N=C2SC(COC)=NN2C=1CN1CC(CC(F)(F)F)CC1=O UBNLUHSOVONECH-UHFFFAOYSA-N 0.000 claims 1
- WZUOWEYSJYNQFH-UHFFFAOYSA-N 1-[[2-(methoxymethyl)-6-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]methyl]-4-(3,3,3-trifluoropropyl)pyrrolidin-2-one Chemical compound FC(F)(F)C=1N=C2SC(COC)=NN2C=1CN1CC(CCC(F)(F)F)CC1=O WZUOWEYSJYNQFH-UHFFFAOYSA-N 0.000 claims 1
- WCUGNFMWFSMXEV-UHFFFAOYSA-N 1-[[6-chloro-2-(methoxymethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]methyl]-4-(2-fluoroethyl)pyrrolidin-2-one Chemical compound ClC=1N=C2SC(COC)=NN2C=1CN1CC(CCF)CC1=O WCUGNFMWFSMXEV-UHFFFAOYSA-N 0.000 claims 1
- 125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 claims 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 1
- DMYQVWBTBYSSPZ-UHFFFAOYSA-N 4-(2-chloro-2,2-difluoroethyl)-1-[[2-(2-methoxyethyl)-6-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]methyl]pyrrolidin-2-one Chemical compound FC(F)(F)C=1N=C2SC(CCOC)=NN2C=1CN1CC(CC(F)(F)Cl)CC1=O DMYQVWBTBYSSPZ-UHFFFAOYSA-N 0.000 claims 1
- NJUMGOFCOKRBAR-UHFFFAOYSA-N 4-(2-chloro-2,2-difluoroethyl)-1-[[2-(hydroxymethyl)-6-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]methyl]pyrrolidin-2-one Chemical compound FC(F)(F)C=1N=C2SC(CO)=NN2C=1CN1CC(CC(F)(F)Cl)CC1=O NJUMGOFCOKRBAR-UHFFFAOYSA-N 0.000 claims 1
- XXUXSYIRKIJMFP-UHFFFAOYSA-N 4-(2-chloro-2,2-difluoroethyl)-1-[[2-(methoxymethyl)-6-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]methyl]pyrrolidin-2-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.FC(F)(F)C=1N=C2SC(COC)=NN2C=1CN1CC(CC(F)(F)Cl)CC1=O XXUXSYIRKIJMFP-UHFFFAOYSA-N 0.000 claims 1
- YXOAMRMNLMTAGB-UHFFFAOYSA-N 4-(2-chloro-2,2-difluoroethyl)-1-[[6-chloro-2-(2,2,2-trifluoroethoxymethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]methyl]pyrrolidin-2-one Chemical compound ClC=1N=C2SC(COCC(F)(F)F)=NN2C=1CN1CC(CC(F)(F)Cl)CC1=O YXOAMRMNLMTAGB-UHFFFAOYSA-N 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 208000001654 Drug Resistant Epilepsy Diseases 0.000 claims 1
- WZKSXHQDXQKIQJ-UHFFFAOYSA-N F[C](F)F Chemical compound F[C](F)F WZKSXHQDXQKIQJ-UHFFFAOYSA-N 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09173912 | 2009-10-23 | ||
| PCT/EP2010/006434 WO2011047860A1 (en) | 2009-10-23 | 2010-10-21 | 2-oxo-1-pyrrolidinyl imidazothiadiazole derivatives |
| EP10781818.9A EP2491045B1 (en) | 2009-10-23 | 2010-10-21 | 2-oxo-1-pyrrolidinyl imidazothiadiazole derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02355B true ME02355B (me) | 2016-06-20 |
Family
ID=42034570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2016-44A ME02355B (me) | 2009-10-23 | 2010-10-21 | Derivati 2-0ks0-1-pirolidinil imidazotiadiazola |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US8822508B2 (OSRAM) |
| EP (1) | EP2491045B1 (OSRAM) |
| JP (1) | JP5808020B2 (OSRAM) |
| KR (1) | KR20120102058A (OSRAM) |
| CN (1) | CN102574869A (OSRAM) |
| AR (1) | AR078722A1 (OSRAM) |
| AU (1) | AU2010310100B2 (OSRAM) |
| BR (1) | BR112012009310B8 (OSRAM) |
| CA (1) | CA2778194C (OSRAM) |
| CL (1) | CL2012001031A1 (OSRAM) |
| CY (1) | CY1117288T1 (OSRAM) |
| DK (1) | DK2491045T3 (OSRAM) |
| EA (1) | EA201200616A1 (OSRAM) |
| ES (1) | ES2565515T3 (OSRAM) |
| HR (1) | HRP20160263T1 (OSRAM) |
| HU (1) | HUE028668T2 (OSRAM) |
| IL (1) | IL218696A0 (OSRAM) |
| IN (1) | IN2012DN02793A (OSRAM) |
| MA (1) | MA33679B1 (OSRAM) |
| ME (1) | ME02355B (OSRAM) |
| MX (1) | MX347070B (OSRAM) |
| PE (1) | PE20121562A1 (OSRAM) |
| PH (1) | PH12012500570A1 (OSRAM) |
| PL (1) | PL2491045T3 (OSRAM) |
| RS (1) | RS54595B1 (OSRAM) |
| SI (1) | SI2491045T1 (OSRAM) |
| SM (1) | SMT201600076B (OSRAM) |
| TN (1) | TN2012000147A1 (OSRAM) |
| TW (1) | TW201118103A (OSRAM) |
| WO (1) | WO2011047860A1 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2699581T3 (en) * | 2011-04-18 | 2016-01-11 | Ucb Biopharma Sprl | 2-oxo-1-IMIDAZOLIDINYLIMIDAZOTHIADIAZOLDERIVATIVER |
| US9581654B2 (en) | 2013-02-12 | 2017-02-28 | Johnson Controls Technology Company | Vehicle battery monitoring system |
| KR20200126026A (ko) | 2014-01-21 | 2020-11-05 | 얀센 파마슈티카 엔.브이. | 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도 |
| MY203464A (en) | 2014-01-21 | 2024-06-28 | Janssen Pharmaceutica Nv | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |
| RU2020104753A (ru) * | 2017-07-10 | 2021-08-10 | Юсб Байофарма Срл | Производные 2-оксо-1, 3-оксазолидинилимидазотиазола |
| EP3652182B1 (en) * | 2017-07-10 | 2021-09-08 | UCB Biopharma SRL | 2-oxo-1-imidazolidinyl imidazothiadiazole derivatives |
| CN107827870B (zh) * | 2017-10-24 | 2019-11-08 | 江苏仁明生物科技有限公司 | 一种正电子药物[18f]fpmmp及其制备方法与中间体 |
| BR112020009880A2 (pt) * | 2017-12-12 | 2020-11-03 | UCB Biopharma SRL | derivados de 2-oxo-1-pirrolidinila imidazotiadiazol |
| EP3790885B1 (en) | 2018-05-08 | 2023-04-19 | UCB Biopharma SRL | 1-imidazothiadiazolo-2h-pyrrol-5-one derivatives |
| CN113549052B (zh) * | 2021-07-09 | 2022-09-02 | 首都医科大学脑重大疾病研究中心(北京脑重大疾病研究院) | 4-苯基-1-（吡啶-4-基甲基）吡咯烷-2-酮衍生物及其制备方法和应用 |
| WO2025132331A1 (en) | 2023-12-21 | 2025-06-26 | UCB Biopharma SRL | Compounds for treatment of a hyperkinetic movement disorder |
| CN119606962B (zh) * | 2025-02-17 | 2025-05-02 | 中国人民解放军总医院第三医学中心 | padsevonil在制备治疗TFE3重排性肾细胞癌的药物中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8412357D0 (en) | 1984-05-15 | 1984-06-20 | Ucb Sa | Pharmaceutical composition |
| GB8412358D0 (en) | 1984-05-15 | 1984-06-20 | Ucb Sa | Pharmaceutical composition |
| GB0004297D0 (en) | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| EP1706376B1 (en) * | 2003-12-02 | 2009-03-04 | UCB Pharma, S.A. | Imidazole derivatives, processes for preparing them and their uses |
| ES2441178T3 (es) * | 2005-06-01 | 2014-02-03 | Ucb Pharma, S.A. | Derivados de 2-oxo-1-pirrolidina, procedimientos para prepararlos y el uso terapéutico de los mismos sobre el sistema nervioso central |
-
2010
- 2010-10-21 CA CA2778194A patent/CA2778194C/en active Active
- 2010-10-21 HU HUE10781818A patent/HUE028668T2/en unknown
- 2010-10-21 PL PL10781818T patent/PL2491045T3/pl unknown
- 2010-10-21 PH PH1/2012/500570A patent/PH12012500570A1/en unknown
- 2010-10-21 PE PE2012000526A patent/PE20121562A1/es not_active Application Discontinuation
- 2010-10-21 EP EP10781818.9A patent/EP2491045B1/en active Active
- 2010-10-21 IN IN2793DEN2012 patent/IN2012DN02793A/en unknown
- 2010-10-21 MX MX2012003839A patent/MX347070B/es active IP Right Grant
- 2010-10-21 RS RS20160156A patent/RS54595B1/en unknown
- 2010-10-21 BR BR112012009310A patent/BR112012009310B8/pt not_active IP Right Cessation
- 2010-10-21 CN CN2010800476319A patent/CN102574869A/zh active Pending
- 2010-10-21 HR HRP20160263TT patent/HRP20160263T1/hr unknown
- 2010-10-21 SI SI201031137T patent/SI2491045T1/sl unknown
- 2010-10-21 TW TW099135866A patent/TW201118103A/zh unknown
- 2010-10-21 JP JP2012534579A patent/JP5808020B2/ja active Active
- 2010-10-21 US US13/502,546 patent/US8822508B2/en active Active
- 2010-10-21 KR KR1020127013216A patent/KR20120102058A/ko not_active Withdrawn
- 2010-10-21 WO PCT/EP2010/006434 patent/WO2011047860A1/en active Application Filing
- 2010-10-21 ME MEP-2016-44A patent/ME02355B/me unknown
- 2010-10-21 DK DK10781818.9T patent/DK2491045T3/en active
- 2010-10-21 EA EA201200616A patent/EA201200616A1/ru unknown
- 2010-10-21 ES ES10781818.9T patent/ES2565515T3/es active Active
- 2010-10-21 AU AU2010310100A patent/AU2010310100B2/en not_active Ceased
- 2010-10-22 AR ARP100103864A patent/AR078722A1/es unknown
-
2012
- 2012-03-18 IL IL218696A patent/IL218696A0/en unknown
- 2012-03-29 TN TNP2012000147A patent/TN2012000147A1/en unknown
- 2012-04-19 MA MA34783A patent/MA33679B1/fr unknown
- 2012-04-23 CL CL2012001031A patent/CL2012001031A1/es unknown
-
2016
- 2016-03-15 CY CY20161100217T patent/CY1117288T1/el unknown
- 2016-03-16 SM SM201600076T patent/SMT201600076B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02355B (me) | Derivati 2-0ks0-1-pirolidinil imidazotiadiazola | |
| JP7575518B2 (ja) | Ｎａｖ１．８阻害剤としての２－オキソイミダゾリジン－４－カルボキサミド | |
| HRP20171999T1 (hr) | Novi derivati aminopirimidina | |
| KR102001745B1 (ko) | 키나제 억제제로서 유용한 인돌 카르복스아미드 화합물 | |
| JP6524081B2 (ja) | ジヒドロピリミジン化合物及び医薬におけるその適用 | |
| PE20090493A1 (es) | DERIVADOS DE LA 6-CICLOAMINO-3-(PIRIDAZIN-4-IL)IMIDAZO[1,2-b]-PIRIDAZINA, SU PREPARACION Y SU APLICACION EN TERAPEUTICA | |
| HRP20151250T1 (hr) | Derivati izoksazolo-piridina | |
| JP2014525432A5 (OSRAM) | ||
| JP6636539B2 (ja) | 変形性関節症の治療のためのａｄａｍｔｓ阻害剤としての５−［（ピペラジン−１−イル）−３−オキソ−プロピル］−イミダゾリジン−２，４−ジオン誘導体 | |
| ME02394B (me) | Pirazolohinolinski derivati kao inhibitori pde9 | |
| HRP20151419T1 (hr) | Derivati 2-okso-1-imidazolidinil imidazotiadiazola | |
| JP2008513516A5 (OSRAM) | ||
| JP2017512789A (ja) | ジヒドロピリミジン化合物及び医薬におけるその適用 | |
| ME02409B (me) | Novi heterociklični derivati i njihova upotreba u tretmanu neuroloških poremećaja | |
| NZ592238A (en) | Pharmaceutical compositions comprising 4-isopropyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine derivatives | |
| HRP20160002T1 (hr) | Bicikliäśki heterocikliäśki spojevi kao inhibitori protein tirozin kinaze | |
| RU2010117156A (ru) | Гетероциклические соединения в качестве антагонистов crth2 рецептора | |
| ZA200600424B (en) | Bicyclic imidazol derivatives against flaviviridae | |
| CN101534824A (zh) | 作为化学活素受体拮抗剂的氨基吡咯烷 | |
| HRP20110458T1 (hr) | Inhibitori rna-ovisne rna-polimeraze iz virusa hepatitisa c, te pripravci i liječenje u kojem se koriste | |
| WO2012122011A2 (en) | Amino-quinolines as kinase inhibitors | |
| JP2016506962A5 (OSRAM) | ||
| RU2006126663A (ru) | Полициклические средства для лечения респираторно-синцитиальных вирусных инфекций | |
| JP2008537930A5 (OSRAM) | ||
| HRP20100180T1 (hr) | Novi spoj piridazina i njegova primjena |